Literature DB >> 31668449

Long-Term Relationship Between Atrial Fibrillation, Multimorbidity and Oral Anticoagulant Drug Use.

Marco Proietti1, Irene Marzona2, Tommaso Vannini2, Mauro Tettamanti2, Ida Fortino3, Luca Merlino3, Stefania Basili4, Pier Mannuccio Mannucci5, Giuseppe Boriani6, Gregory Y H Lip7, Maria Carla Roncaglioni2, Alessandro Nobili2.   

Abstract

OBJECTIVES: To analyze the relationship between atrial fibrillation (AF) and Charlson comorbidity index (CCI) in a population-based cohort study over a long-term follow-up period, in relation to oral anticoagulant (OAC) prescriptions and outcomes. PATIENTS AND METHODS: We used data from the administrative health databases of Lombardy. All patients with AF and age 40 years and older and who were admitted to the hospital in 2002 were considered for analysis and followed up to 2014. AF diagnosis and CCI were established according to codes from the International Classification of Diseases, Ninth Revision.
RESULTS: In 2002, 24,040 patients were admitted with a diagnosis of AF. CCI was higher in patients with AF than in those without AF (1.8±2.1 vs 0.2±0.9; P<.001). Over 12 years of follow-up, AF was associated with an increased risk of higher CCI (beta coefficient, 1.69; 95% CI, 1.67-1.70). In patients with AF, CCI was inversely associated with OAC prescription at baseline (P<.001) and at the end of the follow-up (P=.03). Patients with AF and a high CCI (≥4) had a higher cumulative incidence of stroke, major bleeding, and all-cause death (all P<.001), compared with those with low CCI (range, 0-3). Adjusted Cox regression analysis revealed that time-dependent continuous CCI was associated with an increased risk for stroke, major bleeding, and all-cause death (all P<.001).
CONCLUSIONS: In hospitalized patients, AF is associated with an increase in CCI that is inversely associated with OAC prescriptions during follow-up. CCI is independently associated with an increased risk of stroke, major bleeding, and all-cause death.
Copyright © 2019 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31668449     DOI: 10.1016/j.mayocp.2019.06.012

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  15 in total

1.  Effectiveness and Safety of Oral Anticoagulants in Older Patients With Atrial Fibrillation: A Systematic Review and Meta-Analysis.

Authors:  Maxim Grymonprez; Stephane Steurbaut; Tine L De Backer; Mirko Petrovic; Lies Lahousse
Journal:  Front Pharmacol       Date:  2020-09-09       Impact factor: 5.810

Review 2.  Stroke prevention strategies in high-risk patients with atrial fibrillation.

Authors:  Agnieszka Kotalczyk; Michał Mazurek; Zbigniew Kalarus; Tatjana S Potpara; Gregory Y H Lip
Journal:  Nat Rev Cardiol       Date:  2020-10-27       Impact factor: 32.419

3.  Atrial fibrillation and comorbidities: Clinical characteristics and antithrombotic treatment in GLORIA-AF.

Authors:  Monika Kozieł; Christine Teutsch; Jonathan L Halperin; Kenneth J Rothman; Hans-Christoph Diener; Chang-Sheng Ma; Sabrina Marler; Shihai Lu; Venkatesh K Gurusamy; Menno V Huisman; Gregory Y H Lip
Journal:  PLoS One       Date:  2021-04-14       Impact factor: 3.240

4.  Patient characteristics, adherence, and costs of oral anticoagulation therapy in non-valvular atrial fibrillation using the Dubai Real-World Claims Database.

Authors:  Moutaz El Kadri; Ahmed Ghorab; Jean Joury; Mohamed Farghaly; Nancy Awad; Badarinath Chickballapur Ramachandrachar; Ashok Natarajan
Journal:  Avicenna J Med       Date:  2021-04-19

5.  Use of Non-Vitamin K Antagonist Oral Anticoagulants Among Patients with Nonvalvular Atrial Fibrillation and Multimorbidity.

Authors:  Steven Deitelzweig; Allison Keshishian; Amiee Kang; Amol D Dhamane; Xuemei Luo; Christian Klem; Lisa Rosenblatt; Jack Mardekian; Jenny Jiang; Huseyin Yuce; Gregory Y H Lip
Journal:  Adv Ther       Date:  2021-05-07       Impact factor: 3.845

Review 6.  Optimizing indices of atrial fibrillation susceptibility and burden to evaluate atrial fibrillation severity, risk and outcomes.

Authors:  Giuseppe Boriani; Marco Vitolo; Igor Diemberger; Marco Proietti; Anna Chiara Valenti; Vincenzo Livio Malavasi; Gregory Y H Lip
Journal:  Cardiovasc Res       Date:  2021-06-16       Impact factor: 13.081

7.  The Effects of Implementing a Mobile Health-Technology Supported Pathway on Atrial Fibrillation-Related Adverse Events Among Patients With Multimorbidity: The mAFA-II Randomized Clinical Trial.

Authors:  Yuan Yao; Yutao Guo; Gregory Y H Lip
Journal:  JAMA Netw Open       Date:  2021-12-01

8.  Adherence is an optimal factor for maximizing the effective and safe use of oral anticoagulants in patients with atrial fibrillation.

Authors:  So-Young Yang; Dong-Won Kang; Jin Hyun Nam; Eue-Keun Choi; Eui-Kyung Lee; Ju-Young Shin; Sun-Hong Kwon
Journal:  Sci Rep       Date:  2022-03-01       Impact factor: 4.996

9.  Comprehensive Management With the ABC (Atrial Fibrillation Better Care) Pathway in Clinically Complex Patients With Atrial Fibrillation: A Post Hoc Ancillary Analysis From the AFFIRM Trial.

Authors:  Marco Proietti; Giulio Francesco Romiti; Brian Olshansky; Deirdre A Lane; Gregory Y H Lip
Journal:  J Am Heart Assoc       Date:  2020-05-06       Impact factor: 5.501

10.  Anticoagulation trends in adults aged 65 years and over with atrial fibrillation: a cohort study.

Authors:  Jenny Lund; Catherine L Saunders; Duncan Edwards; Jonathan Mant
Journal:  Open Heart       Date:  2021-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.